Investigator-Initiated Ph 1 Trial for Neoadjuvant ELI-002 7P in Pancreatic Ductal Adenocarcinoma planned
Chief Medical Officer of Elicio Therapeutics, Christopher Haqq, M.D., Ph.D., added, “We believe this study represents a critical step forward in KRAS-targeted immunotherapy. By evaluating ELI-002 in combination with mFOLFIRINOX and exploring the additional role of anti-PD-1 blockade, we aim to establish a treatment paradigm that maximizes immune activation while maintaining safety. Our hope is that this approach will deliver meaningful improvements in relapse-free survival and overall survival for patients facing resectable and borderline resectable PDAC in the neo-adjuvant setting. If Phase 1 results are supportive, expanding to a broader population in this setting could enable more PDAC patients to benefit from ELI-002 7P, and also enhance the commercial opportunity for Elicio.”
Share:
More News
“The positive outcome of our pre-IND interactions with the FDA reinforces the development pathway for MaaT034 and supports its continued advancement toward the clinic. It also represents an important step in MaaT Pharma’s expansion into immuno-oncology, highlighting the broader potential of our first in class co-cultivated microbiome donor-independent platform across
“Patients with metastatic RAS G12D non-squamous NSCLC, occurring in approximately 4% of cases, represent an underserved population, with no approved targeted treatment options. Initial clinical data evaluating zoldonrasib in combination with standard of care pembrolizumab and platinum doublet chemotherapy in patients with previously untreated metastatic RAS G12D non-squamous NSCLC showed
“At Georgiamune, we are focused on uncovering novel mechanisms that control immune-cell function and translating that biology into first-in-class medicines across autoimmune disease and oncology,” said Samir N. Khleif, M.D., Founder and Chief Executive Officer of Georgiamune. “GIM-621 is one of multiple programs to emerge from that work, alongside three
“Our team’s outstanding execution has enabled us to rapidly advance three programs into the clinic in 2026 and make significant progress in developing next-generation IO, ADC and combination therapies. Together with our partner, Kelun-Biotech, we have achieved seven IND clearances to date, and by mid-2027, we expect more than 2,000